Arkolith/Insider Trading/ATYR/Form 4

Shukla Sanjay

President and CEO, DirectoraTYR PHARMA INC (ATYR) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4K
Net Open-Market Flow
-$4K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 4, 2026Sell(S)4K$0.98$4K154K
Feb 3, 2026Option exercise(M)10K——157K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2026Option exercise(M)10K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-038007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML